Compare Sun Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA FRESENIUS KABI ONCO. SUN PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 27.6 22.1 124.9% View Chart
P/BV x 2.4 3.1 76.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 SUN PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
FRESENIUS KABI ONCO.
Mar-13
SUN PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs679176 385.7%   
Low Rs37579 478.2%   
Sales per share (Unadj.) Rs121.137.7 321.5%  
Earnings per share (Unadj.) Rs13.45.1 262.6%  
Cash flow per share (Unadj.) Rs20.76.7 307.7%  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.642.5 405.7%  
Shares outstanding (eoy) m2,399.26158.23 1,516.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.4 128.9%   
Avg P/E ratio x39.425.0 157.7%  
P/CF ratio (eoy) x25.518.9 134.6%  
Price / Book Value ratio x3.13.0 102.1%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,65020,135 6,280.9%   
No. of employees `00017.51.2 1,519.2%   
Total wages/salary Rs m59,671703 8,485.6%   
Avg. sales/employee Rs Th16,608.15,176.2 320.9%   
Avg. wages/employee Rs Th3,409.6610.4 558.6%   
Avg. net profit/employee Rs Th1,833.8699.6 262.1%   
INCOME DATA
Net Sales Rs m290,6595,963 4,874.4%  
Other income Rs m10,25518 56,971.7%   
Total revenues Rs m300,9145,981 5,031.2%   
Gross profit Rs m63,0761,430 4,410.6%  
Depreciation Rs m17,533258 6,798.2%   
Interest Rs m5,553-26 -21,355.8%   
Profit before tax Rs m50,2461,216 4,131.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,144-68 17,832.3%   
Tax Rs m6,009342 1,755.9%   
Profit after tax Rs m32,093806 3,982.3%  
Gross profit margin %21.724.0 90.5%  
Effective tax rate %12.028.1 42.5%   
Net profit margin %11.013.5 81.7%  
BALANCE SHEET DATA
Current assets Rs m310,6925,102 6,090.1%   
Current liabilities Rs m173,3962,385 7,269.1%   
Net working cap to sales %47.245.6 103.7%  
Current ratio x1.82.1 83.8%  
Inventory Days Days99150 66.0%  
Debtors Days Days112113 98.5%  
Net fixed assets Rs m232,4775,148 4,515.8%   
Share capital Rs m2,399158 1,516.6%   
"Free" reserves Rs m411,6916,556 6,280.0%   
Net worth Rs m414,0916,732 6,151.3%   
Long term debt Rs m15,226952 1,599.0%   
Total assets Rs m646,93810,388 6,227.7%  
Interest coverage x10.0-45.8 -22.0%   
Debt to equity ratio x00.1 26.0%  
Sales to assets ratio x0.40.6 78.3%   
Return on assets %5.87.5 77.5%  
Return on equity %7.812.0 64.7%  
Return on capital %10.214.6 69.6%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m66,0255,298 1,246.3%   
Fx outflow Rs m38,6101,772 2,178.7%   
Net fx Rs m27,4153,525 777.6%   
CASH FLOW
From Operations Rs m21,9651,274 1,723.9%  
From Investments Rs m-6,813-1,204 565.7%  
From Financial Activity Rs m-27,305-196 13,924.1%  
Net Cashflow Rs m-8,442-126 6,683.7%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 5.1 0.3 1,710.0%  
FIIs % 23.0 9.6 239.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 9.1 91.2%  
Shareholders   133,026 42,599 312.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 19, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS